Drug Profile
Iroxanadine
Alternative Names: BRX 235Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Biorex
- Developer CytRx Corporation
- Class Cardiotonics; Oxazines; Piperidines; Small molecules
- Mechanism of Action Protein synthesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic foot ulcer; Diabetic neuropathies
- Discontinued Atherosclerosis; Coronary disorders